Lv4
450 积分 2025-06-08 加入
Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States
27天前
已完结
Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
27天前
已完结
Association between pyoderma gangrenosum and autoimmune connective tissue disorders: A systematic review
2个月前
已完结
Targeting Janus kinase 1 in refractory Behçet’s disease: a case report on the clinical efficacy of upadacitinib
2个月前
已完结
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
2个月前
已完结
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
3个月前
已完结
Real-time automated assessment of histological disease activity in patients with ulcerative colitis using single-wavelength endoscopy technology
3个月前
已完结
Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial
3个月前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
7个月前
已完结
皖公网安备34019202002308
